Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in multiple myeloma.

T M Moehler1, J Hillengass, A Glasmacher

  • 1University of Heidelberg, Dept. of Medicine V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Thomas_Moehler@med.uni-heidelberg.de

Current Pharmaceutical Biotechnology
|December 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter re: Ethnic origin in cancer clinical trials: overrated or understated?-A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022.

ESMO open·2025
Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

[Science and reality].

Der Radiologe·2022
Same author

Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Alternative metrics for assessing clinical benefit with immunotherapy in oncology.

Oncoimmunology·2019
Same journal

Comparative Phytochemical Characterization and Antibacterial Activity of Ethanol and Aqueous Extracts of Moringa peregrina and Moringa oleifera against Multidrug-Resistant Bacteria.

Current pharmaceutical biotechnology·2026
Same journal

Unveiling Aptamers for Targeted Tumour Therapies and Detection: Systematic Evolution of Ligands by Exponential Enrichment (SELEX) Technology in Oncology.

Current pharmaceutical biotechnology·2026
Same journal

Nanosuspensions-Based Dry Powder Inhalers for Pulmonary Delivery of Hydrophobic Natural Products: Formulation Strategies, Efficacy, and Challenges.

Current pharmaceutical biotechnology·2026
Same journal

Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Accelerate Diabetic Rat Wound Healing by Inhibiting Pyroptosis through the NLRP3/Caspase-1/GSDMD Pathway.

Current pharmaceutical biotechnology·2026
Same journal

Cyperotundone Regulates Polo-like Kinase 1-mediated Glycolysis to Inhibit the Proliferation of Breast Cancer Cells.

Current pharmaceutical biotechnology·2026
Same journal

Risk Factor Analysis and Nomogram for Predicting 28-day in-hospital Mortality in ICU Patients with Liver Necrosis.

Current pharmaceutical biotechnology·2026
See all related articles

Thalidomide (Thal) is an effective drug for multiple myeloma, significantly improving response rates when combined with other treatments. Strict monitoring is essential due to potential side effects.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Thalidomide (Thal) exhibits antiangiogenic and immunomodulatory properties.
  • Clinical research confirms Thal's efficacy in treating multiple myeloma (MM).

Purpose of the Study:

  • To summarize the evidence supporting Thal's role in multiple myeloma treatment.
  • To highlight Thal's effectiveness in combination regimens and the need for monitoring.

Main Methods:

  • Review of clinical research and randomized trials.
  • Analysis of data on response rates and adverse events.

Main Results:

  • Thal decreases monoclonal protein by at least 50% in 30% of relapsed/refractory MM patients.
  • Thal significantly increases total response rates and decreases time to response in combination therapies (e.g., with dexamethasone).

Related Experiment Videos

Conclusions:

  • Thal is recognized as a key treatment for relapsed or refractory multiple myeloma.
  • Strict guidelines are necessary to manage Thal's teratogenic effects and adverse events like neuropathy and thrombosis.
  • Ongoing studies will further define Thal's role in newly diagnosed patients.